The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a more substantial loss in body